Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Date:3/17/2009

PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical and preclinical abstracts are expected to be the subject of poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2009 in Colorado:

  • "A Phase I, open-label, dose-escalation, multi-dose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin's lymphoma" (Abstract #1227), R. Thertulien - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Efficacy of MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model" (Abstract #838), B. Chen - Poster presentation from 8:00 to 12:00 p.m. local time on Sunday, April 19, 2009.

  • "The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates" (Abstract #1722), S. Gangwar - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Development of anti-Glypican 3 therapeutic antibodies" (Abstract #1233), L. Lu - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19, 2009.

  • "Efficacy and Toxicity of anti-mesothelin antibody drug conjugate" (Abstract #3235), C. Rao - Poster presentation from 8:00 to 12:00 p.m. local time on Tuesday, April 21, 2009.

Abstracts and information about the AACR and its Annual Meeting may be found at www.aacr.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada and Europe. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
2. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
3. Medarex to Present at the RBC Capital Markets Healthcare Conference
4. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
5. Medarex Announces 2008 Third Quarter Financial Results
6. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
7. Medarex to Present at the UBS Global Life Sciences Conference
8. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
9. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
10. Medarex Announces July 10 Live Webcast of R&D Day Event
11. Medarex to Present at the Jefferies Second Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
Breaking Biology Technology:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 The report ... Equipment, Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by ... growing at a CAGR of 29.63% between 2017 and 2022. ... ... Logo ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
Breaking Biology News(10 mins):